Semax (synthetic ACTH analogue)

Tier 3 — weak evidence · Nootropic · Neuroprotection · Synthetic peptide

A synthetic heptapeptide analogue of ACTH(4-10) developed in Russia and approved there for cognitive disorders and stroke recovery. Enhances BDNF expression and modulates dopaminergic and serotonergic systems. Russian clinical data shows improved memory, attention, and stroke recovery. No Western regulatory approval. Administered as a nasal spray. Limited independent replication of Russian studies.

Dose: 200–600 mcg/day intranasal; approved only in Russia and Ukraine; no Western regulatory approval